NICE National Institute for Health and Care Excellence

Resource impact summary report

Resource impact
Published: 30 July 2025

www.nice.org.uk

Contents

Resource impact summary report

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.

Recommendation

Vanzacaftor-tezacaftor-deutivacaftor (Vnz-Tez-Diva) can be used as an option to treat cystic fibrosis in people 6 years and over who have at least 1 F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Vnz-Tez-Diva can only be used if the company provides it according to the commercial arrangement.

Use the least expensive option of the suitable treatments (including Vnz-Tez-Diva and ivacaftor-tezacaftor-elexacaftor [Iva-Tez-Elx]), having discussed the advantages and disadvantages of the available treatments with the person with the condition. Take account of administration costs, dosages, price per dose and commercial arrangements.

Eligible population for Vnz-Tez-Diva

Table 1 shows the population who are eligible for Vnz-Tez-Diva including forecast population growth.

Table 1 Population expected to be eligible for Vnz-Tez-Diva in England

Eligible population (people 6 years and over)	People eligible for Vnz-Tez-Diva
Current practice without Vnz–Tez–Diva	7,459
Year 1	7,525
Year 2	7,591
Year 3	7,658
Year 4	7,725

Eligible population (people 6 years and over)	People eligible for Vnz-Tez-Diva
Year 5	7,793

The following assumptions have been used to calculate the eligible population:

- 9,364 people in England have cystic fibrosis (see the UK Cystic Fibrosis Registry: 2023 Annual Report)
- 89.3% have at least 1 F508del mutation in the CFTR gene
- 7,459 (89.2%) are aged 6 years and over.

Treatment options for the eligible population

Usual treatment for cystic fibrosis with 1 or more F508del mutations in the CFTR gene is Iva-Tez-Elx, which is licensed for people 2 years and over. Vnz-Tez-Diva works in a similar way and is licensed for people 6 years and over.

A cost comparison of Vnz-Tez-Diva and Iva-Tez-Elx in people aged 6 years and over suggests that the costs are similar. Both Iva-Tez-Elx and Vnz-Tez-Diva are oral treatments.

Because Vnz-Tez-Diva has been recommended through the cost-comparison process, NHS England and integrated care boards have agreed to provide funding to implement this guidance 30 days after publication. NHS England has agreed a confidential commercial agreement that enables access to Vnz-Tez-Diva from the date of the final draft guidance.

For more information about the treatments, such as dose and capacity requirements, see the resource impact template. The template incorporates technology appraisal guidance 988, enabling users to model cost and capacity requirements of the cystic fibrosis transmembrane conductance regulator modulators recommended by NICE. For illustration, a 50% shift from Iva-Tez-Elx to Vnz-Tez-Diva is modelled in the template from the first year onwards. Users should override the assumptions to reflect their local populations.

Financial resource impact (cash items)

The company has a commercial arrangement. This makes Vnz-Tez-Diva available to the NHS with a discount.

Users can input the confidential price of Vnz-Tez-Diva and amend other variables in the resource impact template.

The payment mechanism for the technology is determined by the responsible commissioner and depends on the technology being classified as high cost.

For further analysis or to calculate the financial impact of cash items, see the resource impact template.

Capacity impact

The resource impact template can assist with local estimates. The increase in capacity shown in the template is driven only from an expected increase in the eligible population due to population growth. Users are encouraged to input population estimates locally.

For further analysis or to calculate the financial capacity impact from a commissioner (national) and provider (local) perspective, see the resource impact template.

Key information

Table 2 Key information

Time from publication to routine commissioning funding	30 days
Programme budgeting category	04X, Endocrine, Nutritional and Metabolic problems (other)
Commissioner	NHS England
Providers	NHS hospital trusts
Pathway position	Alongside established clinical management

About this resource impact summary report

This resource impact summary report accompanies the NICE technology appraisal guidance on vanzacaftor-tezacaftor-deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over and should be read with it.

ISBN: 978-1-4731-7137-4